Doctors Weigh Patient Goals Instead of ‘Dictating’ Melanoma Treatment
Source: CureToday, April 2024
An expert explained the importance of patient choice in treatment decisions for high-risk, resectable melanoma, based on their own treatment goals.
Treatment via dual checkpoint inhibitors was associated with an increased likelihood of pathological and radiologic responses for patients with high-risk resectable (removable by surgery) melanoma, researchers found.
However, treatment with presurgical standalone anti-PD1 therapy was associated with a lower risk of severe immune-related side effects, while alternative dosing of with dual checkpoint inhibitors was associated with lower immune-related side effect risk with no major difference in efficacy.